http://sarahcannonresearch.com/ News http://www.sarahcannonresearch.com/permalink/cf4ff08a-6d1b-4b7e-8588-1e0b86d44f4d/4e9e5c3e-7088-46f8-ae90-615fdb132250 Thu, 12 Apr 2012 15:22:16 EDT cf4ff08a-6d1b-4b7e-8588-1e0b86d44f4d http://www.sarahcannonresearch.com/permalink/5cf0176e-347a-4561-a208-c862ca235009/4e9e5c3e-7088-46f8-ae90-615fdb132250 NASHVILLE, TN (WSMV) - Her's was a bleak situation. A young Nashville mom's third child was stillborn, then, to make matters worse, the woman was diagnosed with stage four colon cancer. Mon, 26 Mar 2012 10:12:14 EDT 5cf0176e-347a-4561-a208-c862ca235009 http://www.sarahcannonresearch.com/permalink/0f240a95-9bf6-495b-b59d-f83bce8afbb0/4e9e5c3e-7088-46f8-ae90-615fdb132250 A discussion between primary care providers and the oncology multidisciplinary team” event - also known as Oncology 101. The event is a CME program for Primary Care Physicians and advanced practitioners to learn more about oncology care. Thu, 22 Mar 2012 12:18:27 EDT 0f240a95-9bf6-495b-b59d-f83bce8afbb0 http://www.sarahcannonresearch.com/permalink/0f275f86-3b95-4fd3-b324-28cd1fdc5dc9/4e9e5c3e-7088-46f8-ae90-615fdb132250 Congratulations are in order for the Nashville Business Journal’s Forty Under 40 class of 2012. The following 40 winners, first named during a reveal party Tuesday night at Nashville City Club , were deemed to be making a difference in their companies and community by a panel of judges. Thu, 26 Jan 2012 10:56:45 EST 0f275f86-3b95-4fd3-b324-28cd1fdc5dc9 http://www.sarahcannonresearch.com/permalink/fc1126d4-f4a9-4dbf-a01a-59c804ad405e/4e9e5c3e-7088-46f8-ae90-615fdb132250 When it arrives, a diagnosis of cancer can be among the most devastating of news to a patient and their families. For local residents, the course of treatment has often meant weekly trips to nearby Murfreesboro or Nashville for chemotherapy. Mon, 23 Jan 2012 10:32:49 EST fc1126d4-f4a9-4dbf-a01a-59c804ad405e http://www.sarahcannonresearch.com/permalink/8aef4513-0ecc-4653-881a-0dc04ebc4125/4e9e5c3e-7088-46f8-ae90-615fdb132250 NASHVILLE, TN, Jan. 20, 2012 – Sarah Cannon Research Institute (SCRI) physicians authored four abstracts accepted for presentation at the ASCO 2012 Gastrointestinal Cancers Symposium, which runs from Jan. 19-21 in San Francisco, CA. Sat, 21 Jan 2012 12:49:28 EST 8aef4513-0ecc-4653-881a-0dc04ebc4125 http://www.sarahcannonresearch.com/permalink/3bf265bf-40bf-4bf7-9bd4-1e29498fabd9/4e9e5c3e-7088-46f8-ae90-615fdb132250 The Nashville Business Journal is pleased to announce the honorees for this year’s Healthiest Employers Awards. Mon, 19 Dec 2011 12:49:03 EST 3bf265bf-40bf-4bf7-9bd4-1e29498fabd9 http://www.sarahcannonresearch.com/permalink/3ffcadf4-83ab-4e91-ae9b-c0a26930b153/4e9e5c3e-7088-46f8-ae90-615fdb132250 NASHVILLE, TN, Dec. 10, 2011 – Sarah Cannon Research Institute (SCRI) investigators will present the findings of several important blood cancer trials during the 53rd Annual Meeting of the American Society of Hematology (ASH) in San Diego December 10-13. Tue, 13 Dec 2011 16:56:34 EST 3ffcadf4-83ab-4e91-ae9b-c0a26930b153 http://www.sarahcannonresearch.com/permalink/76056d9a-07fd-4ba9-b022-4e0d2dbe56d2/4e9e5c3e-7088-46f8-ae90-615fdb132250 NASHVILLE, TN., Dec. 6, 2011 – Denise A. Yardley, M.D., senior investigator, breast cancer research for Sarah Cannon Research Institute (SCRI) serves as primary or co-author of ten breast cancer clinical trial abstracts that have been accepted for presentation during the 34th Annual San Antonio Breast Cancer Symposium (SABCS), which takes place Dec. 6-10 in San Antonio, Texas. Tue, 06 Dec 2011 16:30:50 EST 76056d9a-07fd-4ba9-b022-4e0d2dbe56d2 http://www.sarahcannonresearch.com/permalink/be702179-b5db-4204-b15c-6d2689f88726/4e9e5c3e-7088-46f8-ae90-615fdb132250 The American Heart Association has awarded 2011 Fit-Friendly recognition to 46 Middle Tennessee companies, for their notable efforts to promote physical activity and health in the workplace, according to an AHA news release. Tue, 22 Nov 2011 10:46:15 EST be702179-b5db-4204-b15c-6d2689f88726 http://www.sarahcannonresearch.com/permalink/98a8bf2b-210c-4e33-bc4d-1667dce39760/4e9e5c3e-7088-46f8-ae90-615fdb132250 Nashville hospitals have something new in their arsenal against the most deadly cancers — emerging vaccines that spur people’s immune systems to target tumors. Mon, 14 Nov 2011 12:07:04 EST 98a8bf2b-210c-4e33-bc4d-1667dce39760 http://www.sarahcannonresearch.com/permalink/c5aeb21a-cca3-464e-af16-dd1bbe8fb0d5/4e9e5c3e-7088-46f8-ae90-615fdb132250 Physician leaders author eight presentations Thu, 17 Nov 2011 18:30:12 EST c5aeb21a-cca3-464e-af16-dd1bbe8fb0d5 http://www.sarahcannonresearch.com/permalink/a7faeba1-f1b1-4656-b1a0-6f933e4a75a4/4e9e5c3e-7088-46f8-ae90-615fdb132250 This is a new addition to our news room that will link to any articles published about Sarah Cannon Research Institute. Thu, 01 Dec 2011 16:27:11 EST a7faeba1-f1b1-4656-b1a0-6f933e4a75a4 http://www.sarahcannonresearch.com/permalink/8f140c0e-3bbe-49fd-8cff-1f7650461188/4e9e5c3e-7088-46f8-ae90-615fdb132250 Wed, 09 Nov 2011 11:20:53 EST 8f140c0e-3bbe-49fd-8cff-1f7650461188 http://www.sarahcannonresearch.com/permalink/310a1321-7f1b-48dd-b67a-9b368d098b89/4e9e5c3e-7088-46f8-ae90-615fdb132250 Speakers, Panelists Share Outlook on Financial Landscape Thu, 03 Nov 2011 13:39:02 EDT 310a1321-7f1b-48dd-b67a-9b368d098b89 http://www.sarahcannonresearch.com/permalink/0c694c29-1456-432d-9b34-4364b4e16515/4e9e5c3e-7088-46f8-ae90-615fdb132250 New technology, treatment options pave way for more companies to enter Mon, 12 Sep 2011 13:15:00 EDT 0c694c29-1456-432d-9b34-4364b4e16515 http://www.sarahcannonresearch.com/permalink/0f1c7651-ba91-46ba-a893-b4e11a1cc48c/4e9e5c3e-7088-46f8-ae90-615fdb132250 NASHVILLE, TN., Sept. 7, 2011 – SCRI Breast Cancer Senior Investigator Denise A. Yardley, M.D. will present findings of ENCORE 301, an advanced breast cancer study, at the 2011 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium September 8-10 in San Francisco, CA. Wed, 07 Sep 2011 17:13:02 EDT 0f1c7651-ba91-46ba-a893-b4e11a1cc48c http://www.sarahcannonresearch.com/permalink/f2b8cc72-2378-4e73-96b5-808f0c8799cc/4e9e5c3e-7088-46f8-ae90-615fdb132250 The FDA approved the melanoma drug vemurafenib along with a companion diagnostic test in a move that was hailed as an advance for both patients and personalized medicine. Fri, 19 Aug 2011 09:38:13 EDT f2b8cc72-2378-4e73-96b5-808f0c8799cc http://www.sarahcannonresearch.com/permalink/296794d5-8757-441e-9e03-f426f73fd772/4e9e5c3e-7088-46f8-ae90-615fdb132250 Searchable directory builds on Best Hospitals rankings Wed, 27 Jul 2011 12:34:54 EDT 296794d5-8757-441e-9e03-f426f73fd772 http://www.sarahcannonresearch.com/permalink/6942b9a6-fd0b-4bac-a173-ab8f8712e02c/4e9e5c3e-7088-46f8-ae90-615fdb132250 NASHVILLE, TN, June 30, 2011 – The International Association for the Study of Lung Cancer (IASLC) has chosen four Sarah Cannon Research Institute (SCRI) abstracts for presentation, including a Conference President’s Selection, at the 14th World Conference on Lung Cancer, which takes place July 3-7 in Amsterdam, The Netherlands. Tue, 12 Jul 2011 15:14:12 EDT 6942b9a6-fd0b-4bac-a173-ab8f8712e02c http://www.sarahcannonresearch.com/permalink/a46a5f80-25b9-45cb-a51a-7ae350303819/4e9e5c3e-7088-46f8-ae90-615fdb132250 NASHVILLE, TN, June 2, 2011 – Sarah Cannon Research Institute (SCRI) has promoted Jeffrey R. Infante, M.D., to Director, Drug Development for the Nashville based program where he previously served as associate director. Howard A. “Skip” Burris III, M.D., chief medical officer for the organization, will assume the role of executive director for the overall drug development initiative. Thu, 02 Jun 2011 14:30:10 EDT a46a5f80-25b9-45cb-a51a-7ae350303819 http://www.sarahcannonresearch.com/permalink/b3c2f7d7-8b4c-4510-a941-c908e0752fb8/4e9e5c3e-7088-46f8-ae90-615fdb132250 Two abstracts chosen for the Best of ASCO program and three for a clinical science symposium Wed, 01 Jun 2011 15:36:55 EDT b3c2f7d7-8b4c-4510-a941-c908e0752fb8 http://www.sarahcannonresearch.com/permalink/d293e24a-1109-4178-bb2e-4408cd4bf6ed/4e9e5c3e-7088-46f8-ae90-615fdb132250 Wed, 01 Jun 2011 15:35:20 EDT d293e24a-1109-4178-bb2e-4408cd4bf6ed http://www.sarahcannonresearch.com/permalink/295e7862-774d-4b59-b628-267873234b5c/4e9e5c3e-7088-46f8-ae90-615fdb132250 NASHVILLE, TN, June 2, 2011 – Sarah Cannon Research Institute (SCRI), one of the largest global clinical research programs, has signed an agreement with The Tampa Bay Heart Institute at Northside Hospital in St. Petersburg, FL, as a cardiovascular clinical research strategic site. Thu, 02 Jun 2011 17:48:17 EDT 295e7862-774d-4b59-b628-267873234b5c http://www.sarahcannonresearch.com/permalink/2139de67-69ef-481c-9f4c-0b65240964ee/4e9e5c3e-7088-46f8-ae90-615fdb132250 Lead article published Wednesday May 25, 2011 in the New England Journal of Medicine featuring SCRI Chief Scientific Officer John D. Hainsworth, M.D. (as co-author of study) on a phase 3 abiraterone study. Fri, 27 May 2011 11:37:57 EDT 2139de67-69ef-481c-9f4c-0b65240964ee http://www.sarahcannonresearch.com/permalink/dc7b0c4a-9bf8-4323-91fc-bb3dd4e40850/4e9e5c3e-7088-46f8-ae90-615fdb132250 Dr. Jesus Berdeja to present results from a Phase 1 study of lorvotuzumab mertansine in combination with Revlimid and dexamethasone in a specific subset of relapsed / refractory myeloma patients whose myeloma cells contain the CD56 protein. Fri, 27 May 2011 11:38:22 EDT dc7b0c4a-9bf8-4323-91fc-bb3dd4e40850 http://www.sarahcannonresearch.com/permalink/074d1be2-957b-4c1c-9840-c1e26cc3d901/4e9e5c3e-7088-46f8-ae90-615fdb132250 Genomic Health Announces Ten Studies Covering Breast, Colon And Prostate Cancers Accepted For Presentation At The American Society Of Clinical Oncology (ASCO) Annual Meeting Fri, 27 May 2011 11:38:43 EDT 074d1be2-957b-4c1c-9840-c1e26cc3d901 http://www.sarahcannonresearch.com/permalink/e6102851-a4d3-41fb-86f2-b003a6801e8c/4e9e5c3e-7088-46f8-ae90-615fdb132250 Fri, 27 May 2011 11:38:47 EDT e6102851-a4d3-41fb-86f2-b003a6801e8c http://www.sarahcannonresearch.com/permalink/3e77353a-8e12-43ea-b807-cadf41982ac0/4e9e5c3e-7088-46f8-ae90-615fdb132250 Fri, 27 May 2011 10:51:50 EDT 3e77353a-8e12-43ea-b807-cadf41982ac0 http://www.sarahcannonresearch.com/permalink/58c2dd1b-962c-4162-bdd9-6442b0f3a608/4e9e5c3e-7088-46f8-ae90-615fdb132250 A Roche Holding AG (ROG) experimental drug called MetMab, used with another medicine, extended the lives of lung-cancer patients whose tumors had high levels of a protein known to trigger the disease and help it spread, a study found. Thu, 19 May 2011 10:22:17 EDT 58c2dd1b-962c-4162-bdd9-6442b0f3a608 http://www.sarahcannonresearch.com/permalink/77488196-dc19-43d3-8f50-3e68fbeb7885/4e9e5c3e-7088-46f8-ae90-615fdb132250 NASHVILLE, TN., May 3, 2011 -- Nine Tennessee physicians affiliated with the Sarah Cannon Research Institute (SCRI) were chosen by fellow physicians as Best Doctors in America for 2011-2012. Wed, 04 May 2011 10:51:25 EDT 77488196-dc19-43d3-8f50-3e68fbeb7885 http://www.sarahcannonresearch.com/permalink/fb4be904-5dfb-4dcc-8ef1-fb13d1c39fc3/4e9e5c3e-7088-46f8-ae90-615fdb132250 Inhibiting two prominent pathways activated in cancer cells appears encouraging in a clinical study • Combination therapy targets MEK and PI3K pathways • Phase I trials of single agent MEK and PI3K pathway inhibitors alone have shown signs of anti-tumor activity • Abstract to be presented at AACR meeting on Sunday, April 3 Wed, 04 May 2011 10:57:34 EDT fb4be904-5dfb-4dcc-8ef1-fb13d1c39fc3 http://www.sarahcannonresearch.com/permalink/509ac2e0-53e4-4499-8075-e85dca6cab23/4e9e5c3e-7088-46f8-ae90-615fdb132250 Former HCA worker to lead financial group at institute Published March 14, 2011 by NashvillePost.com Thu, 31 Mar 2011 17:21:18 EDT 509ac2e0-53e4-4499-8075-e85dca6cab23 http://www.sarahcannonresearch.com/permalink/7daa22cf-f955-422a-84b6-7e4bf385796f/4e9e5c3e-7088-46f8-ae90-615fdb132250 Real-world data have confirmed the effectiveness of a test designed to help identify the primary tumor site in patients with difficult-to-diagnose cancers. After using the novel gene-expression-profile assay, the determination of the primary diagnosis site and treatment management was altered in more than half of the patients in a new study. Tue, 01 Feb 2011 10:43:39 EST 7daa22cf-f955-422a-84b6-7e4bf385796f http://www.sarahcannonresearch.com/permalink/86c456ef-1da4-4032-8bf9-92ca10d32967/4e9e5c3e-7088-46f8-ae90-615fdb132250 Preliminary results of a Phase 2 trial show that the experimental drug panobinostat has little activity in patients with relapsed and resistant myelodysplastic syndromes. Tue, 08 Mar 2011 16:19:49 EST 86c456ef-1da4-4032-8bf9-92ca10d32967 http://www.sarahcannonresearch.com/permalink/0461f167-7623-43e1-bd8f-f81486aef47f/4e9e5c3e-7088-46f8-ae90-615fdb132250 NASHVILLE, TN, Dec. 16, 2010 – Sarah Cannon Research Institute (SCRI) has been selected and has activated an expanded access trial for the treatment of patients with metastatic melanoma. Thu, 16 Dec 2010 20:32:37 EST 0461f167-7623-43e1-bd8f-f81486aef47f http://www.sarahcannonresearch.com/permalink/a2607452-5da5-4db1-87af-0f3d24857688/4e9e5c3e-7088-46f8-ae90-615fdb132250 NASHVILLE, Tenn., Dec. 10, 2010 – David Spigel, M.D., director of lung cancer research at Sarah Cannon Research Institute (SCRI), presented the findings of two clinical trials for lung cancer treatments at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology, which takes place Dec. 9-11. Wed, 15 Dec 2010 12:08:40 EST a2607452-5da5-4db1-87af-0f3d24857688 http://www.sarahcannonresearch.com/permalink/91f7331b-d8a1-495d-ac67-b1f6fc281588/4e9e5c3e-7088-46f8-ae90-615fdb132250 NASHVILLE, Tenn., Dec. 10, 2010 – Sarah Cannon Research Institute (SCRI) investigators will present six breast cancer clinical trial abstracts during the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), which takes place Dec. 8-12 in San Antonio, Texas. Wed, 15 Dec 2010 12:07:31 EST 91f7331b-d8a1-495d-ac67-b1f6fc281588 http://www.sarahcannonresearch.com/permalink/b146701e-8ced-4755-aade-a9246a2ba50e/4e9e5c3e-7088-46f8-ae90-615fdb132250 NASHVILLE, TN., Dec. 6, 2010 – Sarah Cannon Research Institute (SCRI) investigators presented the findings of four key blood cancer trials during the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando. ASH’s annual meeting began Dec. 4 and runs through Dec. 7. Thu, 09 Dec 2010 11:58:06 EST b146701e-8ced-4755-aade-a9246a2ba50e http://www.sarahcannonresearch.com/permalink/5f2b4d0b-834c-471b-8ee3-a8d2c98dedf0/4e9e5c3e-7088-46f8-ae90-615fdb132250 IMGN901 produces no serious toxicities in multiple myeloma patients in early trial Tue, 08 Mar 2011 16:19:42 EST 5f2b4d0b-834c-471b-8ee3-a8d2c98dedf0 http://www.sarahcannonresearch.com/permalink/3960175b-0c02-432d-bb7f-44d72d875aa7/4e9e5c3e-7088-46f8-ae90-615fdb132250 A new drug appears to help chronic myeloid leukemia patients who are out of treatment options after first- and second-line drugs have failed them or because their cancer cells have a mutation that makes them resistant from the start, researchers reported at the 52nd Annual Meeting of the American Society of Hematology Tue, 08 Mar 2011 16:23:25 EST 3960175b-0c02-432d-bb7f-44d72d875aa7 http://www.sarahcannonresearch.com/permalink/82ac4fc8-dbd7-4b08-bc80-4677e069ee54/4e9e5c3e-7088-46f8-ae90-615fdb132250 Tue, 08 Mar 2011 16:22:32 EST 82ac4fc8-dbd7-4b08-bc80-4677e069ee54 http://www.sarahcannonresearch.com/permalink/4d1c82b3-bbb7-44d4-803b-c223074de6f8/4e9e5c3e-7088-46f8-ae90-615fdb132250 The Tennessean, Nov. 21, 2010 Sarah Cannon Research Institute was recognized in Modern Healthcare's Best Places to Work in Healthcare, ranking 48th among 100 companies. Tue, 23 Nov 2010 15:48:19 EST 4d1c82b3-bbb7-44d4-803b-c223074de6f8 http://www.sarahcannonresearch.com/permalink/bc171a10-69a4-4b9f-bf30-fbfb3c7ad0c8/4e9e5c3e-7088-46f8-ae90-615fdb132250 Nashville Post, Nov. 15, 2010 Nashville Post’s Fast50 is our annual look at Middle Tennessee companies on a roll. Together, these companies – as well as the first 25 on our list – represent some of the best the Nashville area has to offer in terms of entrepreneurial vision and growth. Tue, 23 Nov 2010 15:46:28 EST bc171a10-69a4-4b9f-bf30-fbfb3c7ad0c8 http://www.sarahcannonresearch.com/permalink/1bdb68df-29a2-47ac-b0f5-c5693612c263/4e9e5c3e-7088-46f8-ae90-615fdb132250 Sarah Cannon Research Institute quietly opened up shop in London this summer. The Nashville-based business — like a growing number of its local peers — sees enough international growth potential to warrant committing capital. Wed, 24 Nov 2010 10:49:58 EST 1bdb68df-29a2-47ac-b0f5-c5693612c263 http://www.sarahcannonresearch.com/permalink/d3d2cbea-cf3f-40dd-b3d9-c1fcde7791de/4e9e5c3e-7088-46f8-ae90-615fdb132250 Mon, 15 Nov 2010 13:01:47 EST d3d2cbea-cf3f-40dd-b3d9-c1fcde7791de http://www.sarahcannonresearch.com/permalink/57234d5f-963d-4b2a-a780-7bb628f8a992/4e9e5c3e-7088-46f8-ae90-615fdb132250 Tue, 10 Aug 2010 10:58:00 EDT 57234d5f-963d-4b2a-a780-7bb628f8a992 http://www.sarahcannonresearch.com/permalink/9b132d57-020a-4322-916a-c64f2e2d880f/4e9e5c3e-7088-46f8-ae90-615fdb132250 The Best Companies Group has analyzed detailed information provided by numerous Nashville area companies and has in concert with Nashville Post created its annual Best Employers list for the Middle Tennessee region. Thu, 22 Jul 2010 13:58:16 EDT 9b132d57-020a-4322-916a-c64f2e2d880f http://www.sarahcannonresearch.com/permalink/b87dac5d-8124-4dc7-9594-0035a5ffd6b5/4e9e5c3e-7088-46f8-ae90-615fdb132250 Two abstracts chosen for Best of ASCO program Thu, 09 Jun 2011 17:04:04 EDT b87dac5d-8124-4dc7-9594-0035a5ffd6b5 http://www.sarahcannonresearch.com/permalink/94f6280f-adc2-4528-9128-d151ce0d3016/4e9e5c3e-7088-46f8-ae90-615fdb132250 Wed, 27 Oct 2010 16:19:50 EDT 94f6280f-adc2-4528-9128-d151ce0d3016 http://www.sarahcannonresearch.com/permalink/f4fada56-b922-4c20-8317-9581dfb8a932/4e9e5c3e-7088-46f8-ae90-615fdb132250 Mon, 07 Jun 2010 15:55:14 EDT f4fada56-b922-4c20-8317-9581dfb8a932 http://www.sarahcannonresearch.com/permalink/56ce79c6-aa6b-4b3c-9360-5a7a430fa716/4e9e5c3e-7088-46f8-ae90-615fdb132250 Tue, 03 Aug 2010 11:06:13 EDT 56ce79c6-aa6b-4b3c-9360-5a7a430fa716 http://www.sarahcannonresearch.com/permalink/dfbae6d1-f151-4f5d-a810-e5205ff51d52/4e9e5c3e-7088-46f8-ae90-615fdb132250 Dee Anna Smith has helped Sarah Cannon Research Institute create 300 jobs in five years Mon, 24 May 2010 16:21:16 EDT dfbae6d1-f151-4f5d-a810-e5205ff51d52 http://www.sarahcannonresearch.com/permalink/5b3ee819-a3cc-4824-b2d5-a01a7a28f2d2/4e9e5c3e-7088-46f8-ae90-615fdb132250 Thu, 20 May 2010 16:02:03 EDT 5b3ee819-a3cc-4824-b2d5-a01a7a28f2d2 http://www.sarahcannonresearch.com/permalink/eb0290fd-7e01-4139-bd1e-22e19654b483/4e9e5c3e-7088-46f8-ae90-615fdb132250 The Oklahoma Tobacco Settlement Endowment Trust was created in 2000... Tue, 18 May 2010 11:49:24 EDT eb0290fd-7e01-4139-bd1e-22e19654b483 http://www.sarahcannonresearch.com/permalink/8495349c-9b57-48cb-8a20-4ae1018cc50a/4e9e5c3e-7088-46f8-ae90-615fdb132250 Scientists discuss in 'The relationship between bleeding and adverse outcomes in ACS and PCI... Thu, 03 Jun 2010 11:08:56 EDT 8495349c-9b57-48cb-8a20-4ae1018cc50a http://www.sarahcannonresearch.com/permalink/2c1bda3c-12df-47b0-9edd-bf5e08274af6/4e9e5c3e-7088-46f8-ae90-615fdb132250 Thu, 20 May 2010 16:03:24 EDT 2c1bda3c-12df-47b0-9edd-bf5e08274af6 http://www.sarahcannonresearch.com/permalink/1636ae1d-e71e-45d5-b3ef-e46ff791d76e/4e9e5c3e-7088-46f8-ae90-615fdb132250 The head of Tennessee Oncology talks about growing the practice beyond its traditional roots [From our print edition featured in Monday's City Paper] Tue, 18 May 2010 11:45:53 EDT 1636ae1d-e71e-45d5-b3ef-e46ff791d76e http://www.sarahcannonresearch.com/permalink/5e4e4641-2022-4272-a7cb-1bde5566d849/4e9e5c3e-7088-46f8-ae90-615fdb132250 Nashville Clinical Research Education Day is a FREE one-day public education- Sat workshop about the clinical research process and the lifesaving potential for clinical trial participants. Thu, 20 May 2010 16:08:47 EDT 5e4e4641-2022-4272-a7cb-1bde5566d849 http://www.sarahcannonresearch.com/permalink/aa269365-9f50-4805-b0f9-8e9780921dac/4e9e5c3e-7088-46f8-ae90-615fdb132250 Wed, 09 Jun 2010 10:10:14 EDT aa269365-9f50-4805-b0f9-8e9780921dac http://www.sarahcannonresearch.com/permalink/4f183e17-4add-48e0-9123-0734fe3540f0/4e9e5c3e-7088-46f8-ae90-615fdb132250 esophogeal cancer,colorectal cancer,Dr. Spigel, Dr. Bendell,Dr. Infante, Thu, 20 May 2010 16:11:29 EDT 4f183e17-4add-48e0-9123-0734fe3540f0 http://www.sarahcannonresearch.com/permalink/ed34267c-dad3-4b87-b38a-74afb91a90ac/4e9e5c3e-7088-46f8-ae90-615fdb132250 Thu, 03 Jun 2010 13:20:43 EDT ed34267c-dad3-4b87-b38a-74afb91a90ac http://www.sarahcannonresearch.com/permalink/14b75263-4ca2-425b-af2d-c108d226b9a1/4e9e5c3e-7088-46f8-ae90-615fdb132250 Thu, 03 Jun 2010 23:27:23 EDT 14b75263-4ca2-425b-af2d-c108d226b9a1 http://www.sarahcannonresearch.com/permalink/62637e5d-d018-456a-ab27-f0c7dba06fdb/4e9e5c3e-7088-46f8-ae90-615fdb132250 Thu, 03 Jun 2010 23:28:29 EDT 62637e5d-d018-456a-ab27-f0c7dba06fdb http://www.sarahcannonresearch.com/permalink/fb9d0c71-404d-4803-b29b-767b080c914d/4e9e5c3e-7088-46f8-ae90-615fdb132250 Thu, 03 Jun 2010 23:29:40 EDT fb9d0c71-404d-4803-b29b-767b080c914d http://www.sarahcannonresearch.com/permalink/71d18bd3-c288-4100-99fe-4432a5e79f1c/4e9e5c3e-7088-46f8-ae90-615fdb132250 Thu, 03 Jun 2010 23:30:47 EDT 71d18bd3-c288-4100-99fe-4432a5e79f1c http://www.sarahcannonresearch.com/permalink/118f49b5-4624-4650-96c7-688955a22548/4e9e5c3e-7088-46f8-ae90-615fdb132250 Thu, 03 Jun 2010 23:31:54 EDT 118f49b5-4624-4650-96c7-688955a22548 http://www.sarahcannonresearch.com/permalink/fcc73f19-b5b9-474a-a1d3-95c15f65c204/4e9e5c3e-7088-46f8-ae90-615fdb132250 Thu, 03 Jun 2010 23:32:56 EDT fcc73f19-b5b9-474a-a1d3-95c15f65c204 http://www.sarahcannonresearch.com/permalink/4e2928bd-947f-4166-86f2-0344578addf0/4e9e5c3e-7088-46f8-ae90-615fdb132250 Thu, 03 Jun 2010 23:34:27 EDT 4e2928bd-947f-4166-86f2-0344578addf0 http://www.sarahcannonresearch.com/permalink/1bc4c00c-72de-4af6-90ae-ee324d12e68d/4e9e5c3e-7088-46f8-ae90-615fdb132250 Three Tennessee companies make the list Wed, 26 May 2010 12:25:59 EDT 1bc4c00c-72de-4af6-90ae-ee324d12e68d http://www.sarahcannonresearch.com/permalink/190e2cc4-5f33-4c90-bb4c-37e5551cf12e/4e9e5c3e-7088-46f8-ae90-615fdb132250 Thu, 03 Jun 2010 23:35:16 EDT 190e2cc4-5f33-4c90-bb4c-37e5551cf12e http://www.sarahcannonresearch.com/permalink/d2fa0428-cacb-4953-aab2-843a6624e3f8/4e9e5c3e-7088-46f8-ae90-615fdb132250 Thu, 03 May 2012 11:27:56 EDT d2fa0428-cacb-4953-aab2-843a6624e3f8